Popular Articles

Ilaris® Recommended For European Approval As New Biologic Drug To Treat A Rare But Serious Group Of Auto-inflammatory Diseases
The biotechnology medicine Ilaris® (canakinumab) has passed another major milestone with a recommendation for approval in the European Union to treat patients with a life-long and potentially fatal auto-inflammatory disease called cryopyrin-associated periodic syndrome (CAPS). When approved, Ilaris will be the only treatment in the EU indicated for CAPS patients aged four years and older[1].
drugs without prescription
Bovie Medical Corporation Announces FDA Submission Of Laparoscopic Device For Solid Organ Resection
Bovie Medical Corporation (the "Company") (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, announced a 510K submission to the FDA seeking pre-market clearance for a laparoscopic SEER device for solid organ resection. The laparoscopic SEER is a line extension of the Saline Enhance Electrosurgical Resection (SEER) device that Bovie launched earlier this year and will address the growing market of minimally invasive liver resection.
News of the day
Hearing Loss More Prominent In Men, Says Miracle-Ear
When it comes to maintaining their health, men tend to wait for serious symptoms to appear before taking the necessary precautions. Indications of serious physical conditions, however, can oftentimes take a silent form. Take hearing loss: The condition affects more than 31 million people, 65 percent of whom are men, but the signs of the condition are typically overlooked. With that in mind, Miracle-Ear is honoring National Men"s Health Week, which begins on June 15th, with advice on what to look - or listen - for to determine if men are living with diminished hearing capacity.
Oncology

Study To Follow Pregnant Women To Better Understand Causes, Early Signs Of Autism

NIH and the advocacy group Autism Speaks are enrolling 1,200 pregnant women who have other children with autism spectrum disorders to participate in a large study that aims to identify early signs of the condition and its possible causes, the Wall Street Journal reports. Women who participate in the study -- known as the Early Autism Risk Longitudinal Investigation, or EARLI, study -- will be monitored throughout their pregnancies, and their infants will be monitored until age three. The Centers for Disease Control and Prevention estimates that one in 150 children in the U.S. has an autism spectrum disorder, which includes autism, Asperger"s syndrome and pervasive developmental disorders. The study will focus on women who already have one child with an autism spectrum disorder because such women have a higher chance of having another child with the condition. Craig Newschaffer, the study"s lead investigator and a department chair at Philadelphia"s Drexel University School of Public Health, said, "By studying families who are already affected by autism, we feel we have the best chance at learning how genetics and environmental factors could work together to cause autism." Autism usually is characterized by social interaction and communication impairments, as well as unusual interests or behaviors. Although there is no cure for autism, its symptoms can be improved through therapy and medication, the Journal reports.According to Newschaffer, researchers throughout the study will collect blood and urine for DNA analysis. Samples also will be collected from the umbilical cord, placenta and meconium -- the infant"s first stool -- after birth. Infants born during the study will be provided with a series of developmental assessments, and older siblings with autism also could receive assessments to confirm their diagnosis (Corbett Dooren, Wall Street Journal, 6/9). Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women"s Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women"s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company. © 2009 The Advisory Board Company. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):